

Attorney Docket No. VPI/02-116 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/700,333
Confirmation No.: 5159
Filing Date: November 3, 2003
Examiner: Venkataraman Balasubramanian
Group Art Unit: 1624
Applicants: Mark Ledebuer et al.
For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER
PROTEIN KINASES

RECEIVED
CENTRAL FAX CENTER
DEC 21 2006

December 21, 2006
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

- (a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.
- ☒ Copy(ies) of references Citation No(s). C1, C2, and C3 are attached.
- ☐ Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.
- ☐ A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.
- (b) ☐ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

12/26/2006 HDEHES1 00000063 500725 10700333
01 FC:1806 180.00 DA


Rev. 3/2/05

Applicants: Mark Ledebner et al.
Application No.: 10/700,333

- ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☒ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☒ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Applicants: Mark Ledebøer et al.
Application No.: 10/700,333

Respectfully submitted,



Karen E. Brown, Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483

RECEIVED
CENTRAL FAX CENTER

042/065

DEC 21 2006

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/700,333
	Filing Date	November 2, 2003
	First Named Inventor	Mark Ledebner
	Group Art Unit	1624
	Examiner Name	Venkataraman Balasubramanian
	Attorney Docket Number	VPI/02-116 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date/ Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Changelian et al., "Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor," Science, 302:875-878, (2003).
	C2	Malaviya et al., "Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3',5' - dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97)," The Journal of Pharmacology and Experimental Therapeutics, 295(3):912-926, (2000).
	C3	Trieu et al., "A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis," Biochemical and Biophysical Research Communications, 267:22-25, (2000).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.